title: [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
abstract: OBJECTIVE
  To assess the economic evaluation of short- and long-term antiviral treatments of HBeAg-positive chronic hepatitis B from the perspective of the Chinese health care system.
  
  
  METHODS
  A 10-health state Markov model was developed to estimate long-term cost and effectiveness of different treatments of HBeAg-positive CHB. Incremental cost-effectiveness analysis was then carried out.
  
  
  RESULTS
  In comparison with no antiviral treatment, lamivudine administered for 1-year was a highly cost-effective short-course treatment for HBeAg-positive CHB. However, of the treatments evaluated, lamivudine plus adefovir as a rescue medication or adefovir plus lamivudine as a rescue medication administered for 5 years resulted in a more sustained decrease in the rate of disease progression. In comparison with 1 year lamivudine treatment, the incremental cost per Quality Adjusted Life Year (QALY) for treatment with lamivudine plus adefovir or adefovir plus lamivudine as a rescue medication for 5 years was CNY 25 115 and 35 577 respectively, which was 55.2% and 36.5% lower than the estimated international threshold value for China.
  
  
  CONCLUSIONS
  In comparison with no antiviral treatment, lamivudine administered for 1-year is a highly cost-effective short-course treatment. Longer duration antiviral treatments, lamivudine plus adefovir or adefovir plus lamivudine as a rescue medication are both cost-effective strategies, resulting in a more sustained decrease in the rate of disease progression.
authors.affiliation: LaceySolutions Ltd., The Beaches, South Strand, Skerries, County Dublin, Republic of Ireland.
authors.forename: Lacey
authors.initials: L
authors.lastname: Larry
authors.forename: Xian-zhong
authors.initials: XZ
authors.lastname: Lu
authors.forename: Tan
authors.initials: T
authors.lastname: Alison
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives / Q000191:economics / Q000627:therapeutic use; D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis / Q000191:economics; D005260:Female; D006513:Hepatitis B e Antigens / Q000097:blood; D019694:Hepatitis B, Chronic / Q000097:blood / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D019259:Lamivudine / Q000191:economics / Q000627:therapeutic use; D008297:Male; D063065:Organophosphonates / Q000191:economics / Q000627:therapeutic use; D019057:Quality-Adjusted Life Years; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; D019259:Lamivudine; C053001:adefovir; D000225:Adenine